Bertilimumab Biosimilar – Anti-CCL11 mAb – Research Grade

Description of Bertilimumab Biosimilar - Anti-CCL11 mAb - Research Grade

Bertilimumab Biosimilar – Anti-CCL11 mAb – Research Grade Bertilimumab Biosimilar – Anti-CCL11 mAb – Research Grade Introduction

Bertilimumab is a biosimilar of the monoclonal antibody (mAb) targeting CCL11, also known as eotaxin-1. It is a research grade antibody that has shown promising results in preclinical studies and is currently being evaluated for its potential therapeutic applications.

Structure

Bertilimumab is a fully humanized IgG1 kappa mAb with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to its target, CCL11, while the constant region mediates effector functions such as complement activation and antibody-dependent cellular cytotoxicity.

Activity

CCL11 is a chemokine that plays a key role in the recruitment and activation of eosinophils, a type of white blood cell involved in allergic and inflammatory responses. Elevated levels of CCL11 have been associated with various diseases such as asthma, atopic dermatitis, and eosinophilic esophagitis. Bertilimumab binds to CCL11 with high affinity and blocks its interaction with its receptor, thereby inhibiting the recruitment and activation of eosinophils. This leads to a reduction in inflammation and tissue damage associated with these diseases.

Application

Bertilimumab is being investigated for its potential therapeutic applications in various diseases where CCL11 plays a role. These include:

• Asthma: In a preclinical study, Bertilimumab showed a significant reduction in airway inflammation and hyperreactivity in a mouse model of asthma. It is currently in a Phase 2 clinical trial for the treatment of severe, uncontrolled asthma.
• Atopic dermatitis: In a Phase 2 clinical trial, Bertilimumab demonstrated a significant improvement in the severity of atopic dermatitis symptoms, including itching and skin lesions.
• Eosinophilic esophagitis: In a Phase 2 clinical trial, Bertilimumab showed a significant reduction in eosinophilic esophagitis symptoms and esophageal tissue damage.

Conclusion

Bertilimumab is a promising biosimilar of the anti-CCL11 mAb that has the potential to be an effective treatment for various diseases associated with elevated levels of CCL11. Its unique mechanism of action and favorable safety profile make it a promising candidate for further clinical development. Further studies are needed to fully evaluate its efficacy and safety in different disease indications.

Keywords

Antibody, therapeutic target, Bertilimumab, biosimilar, monoclonal antibody, CCL11, eotaxin-1, research grade, structure, activity, application, asthma, atopic dermatitis, eosinophilic esophagitis.